Dr. Lin Jialiang Appointed Vice Chair of CBIITA Nucleic Acid Therapeutics Committee; HaiChang Bio Announces Recent Prospectus Filing

Dec 27, 2024 13:50 CST Updated 13:50

Haichang Biotech

Innovative Formulation Developer

At the 6th China Biomedical Industry Chain Innovation and Transformation Forum, which recently concluded successfully in Guangzhou, Dr. Jialiang Lin, Head of Delivery System Research and Development at the Nucleic Acid Innovation Research Institute of Zhejiang Haichang Biomedical Technology Co., Ltd., was invited to attend. In recognition of his outstanding contributions and profound expertise in the biomedical field, he was honored with the position of Vice Chairman of the Nucleic Acid Drug Professional Committee of the China Biomedical Industry Chain Innovation and Transformation Alliance (CBIITA). This honor was personally conferred by academicians Kaisong Chen and Zixin Deng.

This conference, themed "Open Innovation, Integrated Chain for Common Growth," focuses on the development positioning of China's biopharmaceutical industry during the country’s “15th Five-Year Plan” period. It thoroughly explores paths to promote high-quality development in the biopharmaceutical industry through multi-dimensional means such as technological innovation, policy guidance, and capital support, aiming to drive the high-quality growth of the biopharmaceutical sector.

Dr. Lin Jialiang's appointment as the Vice Chairman of the Special Committee is not only an affirmation of his personal professional capabilities but also a profound recognition of Haichang Biotech's outstanding strength in the field of nucleic acid drugs. We will uphold the spirit of continuous exploration and relentless innovation, committing ourselves to playing a more active role in the biopharmaceutical industry and contributing our expertise to the advancement and development of the entire sector. Looking ahead, we eagerly anticipate that Haichang Biotech can join hands with more like-minded partners in the industry’s exchange and cooperation, to jointly create an even more brilliant future!

About Haichang Biotech

Haichang Biotech, located in China Medical Valley, Hangzhou, is a national-level specialized and innovative "little giant" enterprise that focuses on the technological innovation and development of biopharmaceuticals, integrating research, production, and sales of pharmaceuticals. The company adheres to its core values of "sharing, progress, truth-seeking, and pragmatism," with a focus on the development and industrialization of drug delivery systems. It specializes in the development of nucleic acid innovative drugs such as small nucleic acid drugs, mRNA vaccines, and complex injectables. Currently, Paclitaxel for Injection (Albumin-Bound) has been approved in nearly 40 countries, including China, the UK, and the EU, with ongoing registration in multiple Belt and Road countries. HC0301, a novel Class 1 small nucleic acid drug, has received dual approval from the FDA and NMPA and is undergoing global multi-center Phase II clinical trials. The mRNA COVID-19 vaccine booster has been approved for clinical trials by the FDA, making it the first Chinese-produced mRNA vaccine product to receive clinical approval in the United States. The product pipeline covers areas such as anti-tumor, tumor immunotherapy, analgesia, and infectious disease prevention.